The MetroHealth System is part of a study called Prehospital Air Medical Plasma Trial (PAMPer). Individuals experiencing hemorrhagic shock (uncontrolled bleeding) will be given two units of plasma while in the helicopter on the way to the hospital by Metro Life Flight.
People in this study will be unable to give informed consent because they will be experiencing life-threatening bleeding and shock, and the treatment must be started immediately in the helicopter on the way to the trauma center. This study will be conducted under the FDA exception-from-informed consent process. Before starting the study, MetroHealth educated the public about the upcoming research, which includes community consultation and public notification.
This research will look to see if there is a benefit to delivering treatment that is normally given in the hospital at an earlier time, while in air transport. MetroHealth and its partners will look at what happens to people who are given plasma on the way to the hospital and study their clinical outcomes including:
1) Will bleeding stop earlier
2) Will people require less blood to be given
3) Will people have less serious medical problems
4) Will people get less infections in the hospital
5) Will there be a lower incidence of Acute Lung Injury and transfusion related to Acute Lung Injury.
“This study is taking standard of care and making it happen sooner.” said Jeffrey Claridge, MD, Director of Trauma, Critical Care and Burns at MetroHealth.
Metro Life Flight will enroll research participants with blunt or penetrating trauma and hemorrhagic shock who are being transported to MetroHealth Medical Center. Metro Life Flight already carries red blood cells for transfusion in these individuals. Plasma will be given to individuals as part of this research study. Plasma has not been available in the helicopter before, because there are many logistical issues related to coordinating between helicopters and the blood bank. For example, plasma is stored in a freezer and it takes time to thaw the plasma before giving it to people. This is difficult to do when in an emergency situation.
If MetroHealth and its partners discover through their research that giving plasma on the way to the hospital helps injured people, we can improve the way emergency services use plasma nationwide.
“We were approached to be part of this very high-level study,” Dr. Claridge told The Plain Dealer. “Metro is a fantastic trauma hospital and the fact that we’re part of a Department of Defense study is an incredible thing for Cleveland and Northeast Ohio.”
The study will be conducted over four years. Patients must be 18 – 90 years old with low blood pressure or bleeding that does not get better with standard treatment.
Community members who do not wish to participate in this research study can obtain a bracelet to opt out. Please visit www.metrohealth.org/pamper for more information or call 412-864-1599.
- Jhonlin Air Transport to add Airbus H145
- Metro Delivers New Aircraft to University of Chicago
- Mercyhealth REACT Has New Helicopter in Service
- PAC International completes EC145 refurbishment
- ATP improves torquing method for Airbus EC145
- Duke Life Flight EC145 crash leads to lawsuit against Safran and pilot
- Anti-corruption questions over Airbus EC145 sale to Kazakhstan
- Airbus shows H130 and EC145 at AMTC 2017
- Travis County to sell UH-1 and replace EC145s
- Uralhelicom sees increase in new helicopter sales
- The French Gendarmerie Nationale Orders an Additional EC145
- Iraq Ministry of Oil receives four EC145s
- The Helicopter Flight Training Center goes international
- New Location is LifeFlight’s First in Northwest Pennsylvania
- NZ CAA approves Metro Aviation EC145 simulator
- 22-May-17 AN-136 Eurocopter EC145 Punta Chame, Panama
- 19-May-17 N197LL Airbus EC145 Terre Haute, US-Indiana
- SAFE Structure delivers hangar equipment to New Mexico Army National Guard
- STAT Medevac Selects SKYTRAC for HAA-Compliant Flight Data Monitoring
- Milestone places €200 million firm order with Airbus Helicopters for H135, H145 and H175